What Is CHD in a Blood Test: Your Lab Results Explained

CHD on a blood test almost always refers to coronary heart disease, the condition where fatty deposits narrow the arteries supplying your heart. Your doctor uses a collection of blood markers, especially a lipid panel, to estimate your risk of developing or worsening CHD. Less commonly, CHD can appear in lab paperwork as an abbreviation for cold agglutinin disease (sometimes called cold hemagglutinin disease) or congenital heart disease, each of which involves very different blood tests and clinical situations. Understanding which version your results are talking about, and what the numbers actually mean, can save you a lot of unnecessary worry or, in some cases, prompt the follow-up conversation you actually need.

The Standard Lipid Panel and CHD Risk

When a blood test is ordered to assess CHD risk, the core report is a lipid panel. It measures total cholesterol, LDL cholesterol (often called “bad” cholesterol), HDL cholesterol (“good” cholesterol), and triglycerides. Each of these has been linked to the likelihood of developing coronary heart disease. A large prospective study across racially diverse populations found that per standardized increase, total cholesterol, triglycerides, and LDL cholesterol each raised the odds of CHD, while higher HDL cholesterol lowered it. Specifically, the odds ratios per one standard deviation increase were about 1.33 for total cholesterol, 1.32 for triglycerides, 1.24 for LDL cholesterol, and 0.79 for HDL cholesterol.¹

A century of research has established that LDL is the primary culprit in the buildup of arterial plaques. LDL particles deposit cholesterol in artery walls, triggering inflammation and gradually narrowing the vessels that feed the heart muscle. People with genetic conditions that dramatically raise LDL can suffer heart attacks in childhood, while those with mutations that lower LDL enjoy significantly less heart disease. That causal chain is one of the best-established relationships in cardiovascular medicine, and it’s why your doctor pays so much attention to LDL on your lab report.

Why Ratios Can Tell You More Than Single Numbers

If you look only at your LDL number, you can miss part of the picture. Several studies have found that the ratio of total cholesterol to HDL cholesterol is a stronger predictor of heart disease risk than LDL alone. In the Quebec Cardiovascular Study, the total cholesterol to HDL ratio was the single best predictor of ischemic heart disease risk among men, outperforming the LDL-to-HDL ratio.² A more recent study confirmed that the total cholesterol to HDL ratio was independently associated with coronary atherosclerosis, and its values climbed as the number of diseased vessels increased.³

Here is why this matters practically: you can have an LDL below the commonly reassuring threshold of 100 mg/dL and still carry elevated risk. Among apparently healthy people with low LDL, those whose total cholesterol to HDL ratio exceeded 5 had roughly double the risk of future CHD compared with those whose ratio was below 5. Even elevated triglycerides in this low-LDL group raised the risk substantially.⁴ So if your lab printout shows a low LDL but a high total cholesterol to HDL ratio, that is worth discussing with your doctor rather than assuming everything looks fine.

Advanced Markers Your Doctor Might Order

A standard lipid panel is the starting point, but it is not the whole story. When risk seems higher than the basic numbers explain, or when someone already has diabetes or early-onset heart disease in the family, additional blood markers can sharpen the picture.

One increasingly studied measure involves apolipoproteins, which are the proteins that ride on lipoprotein particles. ApoB is carried on LDL and other harmful particles, while ApoA1 travels with HDL. In people with type 2 diabetes, the ratio of ApoB to ApoA1 showed a stronger correlation with CHD risk than traditional LDL or even the non-HDL-to-HDL ratio.⁵ Newer research has gone further, developing a “risk-weighted” ApoB measurement that accounts for the fact that not all ApoB-carrying particles are equally dangerous. This metric improved risk prediction significantly compared with standard ApoB alone.⁶

High-sensitivity C-reactive protein, or hs-CRP, is another blood test that shows up in CHD workups. It measures inflammation in the body rather than cholesterol directly. In older patients already diagnosed with coronary heart disease, the ratio of hs-CRP to HDL cholesterol was an independent predictor of how severe the arterial narrowing was.⁷ These markers are not part of a routine checkup for most people, but if your lab results include ApoB, ApoA1, lipoprotein(a), or hs-CRP, your doctor is looking beyond the basics for a more detailed risk profile.

Do You Need to Fast Before a Lipid Test?

For decades, patients were told to fast for 9 to 12 hours before a cholesterol blood draw. The reasoning was simple: eating raises triglycerides temporarily, which in turn throws off the formula used to estimate LDL. That formula, developed in the 1970s, loses accuracy when triglycerides are elevated. Guidelines have softened considerably on this point, though, and many doctors now accept non-fasting lipid panels as clinically useful.

The maximal average shifts between fasting and non-fasting samples are modest for most values: triglycerides go up by about 26 mg/dL, while total cholesterol, LDL, and non-HDL cholesterol each dip by around 8 mg/dL. HDL and ApoB barely budge.⁸ For most clinical decisions, those shifts do not change which risk category you fall into. A newer method for estimating LDL performs well in both fasting and non-fasting samples, with accuracy between roughly 87% and 94% across clinical categories, compared with as low as 37% for the older formula when triglycerides were high in non-fasting patients.⁹

If you are on a statin, the fasting question comes up frequently. Research on this point has found that the differences between fasting and non-fasting lipid values are not affected by the type or duration of statin use, supporting the idea that non-fasting draws are clinically acceptable for people on these medications.¹⁰ The bottom line: if your doctor says you don’t need to fast, they are following current evidence. If they still ask you to fast, it is likely because they want triglycerides measured precisely or because your previous results were borderline.

Medications and Conditions That Shift Your Numbers

Your lipid results do not exist in a vacuum. A wide range of commonly prescribed drugs can push cholesterol and triglycerides in directions that have nothing to do with your diet or exercise habits. Certain blood pressure medications, older oral contraceptives, immunosuppressive drugs, and some antiseizure medications can raise total cholesterol, LDL, or triglycerides substantially. In some cases, triglycerides can increase by up to 300% and HDL can drop by half.¹¹ On the flip side, estrogen-based therapies and some newer contraceptive formulations tend to improve the lipid profile. If your numbers have shifted unexpectedly, any new medication you started in recent months is worth mentioning to whoever is reviewing your results.

Underlying health conditions also matter. Chronic kidney disease, for instance, amplifies the relationship between lipid levels and heart disease risk. In community-dwelling adults, higher non-HDL cholesterol was associated with greater CHD risk in both those with and without kidney disease, but the association was stronger in the kidney disease group. People with kidney disease and non-HDL cholesterol at or above 190 mg/dL had roughly triple the CHD risk compared with those below 150 mg/dL.¹² Chronic kidney disease patients also tend to have elevated remnant cholesterol and hs-CRP, both of which independently raise CHD risk in a dose-dependent way.¹³ Thyroid dysfunction and diabetes are other conditions that commonly distort lipid panels.¹⁴

How Blood Test Results Feed Into Risk Calculators

A single cholesterol number does not tell you whether you will have a heart attack. The medical field uses risk calculators that combine your blood test values with other information, including your age, sex, blood pressure, smoking status, and whether you have diabetes. The most widely used tool in the United States for adults aged 40 to 75 is the Pooled Cohort Equations, which estimates your ten-year risk of a major cardiovascular event like a heart attack or stroke.¹⁵ That calculated percentage, rather than any individual lipid number, often drives the decision about whether to start a statin or intensify lifestyle changes.

These calculators have limitations. A newer model called PREVENT has been introduced alongside the older Pooled Cohort Equations, and the two do not always agree. In a large analysis from the NIH All of Us Research Program, overall statin eligibility was about 23% under PREVENT compared with 28% under the older equations. The biggest differences showed up in adults aged 60 to 69 and in Black participants, where the gap between the two calculators was widest.¹⁶ If your doctor mentions your “ASCVD risk score” alongside your lipid results, that is what they are calculating, and it is worth asking which version of the calculator was used if the result seems surprising.

When CHD on a Lab Report Means Cold Agglutinin Disease

In hematology, CHD sometimes stands for cold hemagglutinin disease, more formally called cold agglutinin disease. This is a rare autoimmune condition in which antibodies produced by the body’s own immune cells attack red blood cells at low temperatures. It accounts for roughly 15% to 25% of all autoimmune hemolytic anemia cases.¹⁷ It is a completely different condition from coronary heart disease, and the blood tests used to detect it are entirely different from a lipid panel.

The hallmark antibodies involved are usually IgM class, and they need to reach a certain concentration, typically a titer of at least 1:64 at 4°C, to be clinically significant.¹⁸ These antibodies cause red blood cells to clump together when blood cools, which triggers the immune system’s complement pathway to destroy them. Most of that destruction happens in the liver, though during flare-ups, red cells can break apart directly in the bloodstream.¹⁷ Laboratory testing for cold-reactive autoantibodies is labor-intensive and not always ordered appropriately. A direct antiglobulin test (sometimes called a Coombs test) is typically the first step before more specific cold agglutinin testing is pursued.¹⁹

One way cold agglutinin disease can show up unexpectedly is through bizarre-looking results on a routine complete blood count. Because the antibodies make red blood cells stick together, the automated analyzers that count blood cells get confused. The clumps are counted as single large cells or excluded entirely, leading to a falsely low red blood cell count, a falsely high mean cell volume (MCV), and a mismatch between hemoglobin and hematocrit that doesn’t make physiological sense.²⁰ If your lab flags a hemoglobin-hematocrit discrepancy and the values seem internally contradictory, cold agglutinins are one of the classic causes. The fix in the lab is straightforward: warming the blood sample to 37°C before running it through the analyzer breaks apart the clumps and yields accurate numbers.²¹

CHD as Congenital Heart Disease in Newborn Screening

In pediatric and obstetric medicine, CHD most often stands for congenital heart disease, meaning structural heart defects present from birth. These range from small holes between heart chambers that close on their own to complex malformations requiring surgery in the first days of life. Blood tests in this context look nothing like a lipid panel. The focus is on biomarkers that indicate cardiac stress in a newborn.

A recent study tested a dried blood spot screening approach combining two markers, NT-proBNP and a protein called IL-1 RL1, to identify high-risk congenital heart disease in newborns. The combined test achieved roughly 93% accuracy, with sensitivity around 94% and specificity around 92%. Critically, about one in five high-risk CHD cases in the study had been missed by standard prenatal ultrasound and postnatal pulse oximetry screening. Of those missed cases, 86% were flagged by the blood spot test.²² Separately, researchers are exploring whether DNA methylation patterns in amniotic fluid can detect congenital heart disease prenatally. A predictive model based on methylation at four sites within the PCNT gene showed specificity above 80% and variable sensitivity across different cohorts and types of defects.²³

If you are seeing CHD on a lab report in the context of pregnancy or a newborn, the doctors involved are screening for structural heart problems, not cholesterol. The abbreviation is the same, but the tests, the conditions, and the follow-up actions are worlds apart.

Who Gets Tested and Who Gets Missed

One often-overlooked aspect of CHD blood testing is who receives it in the first place and at what age. A large analysis of over half a million adults in Pakistan found that women had their first lipid tests significantly later in life than men, despite having higher average LDL cholesterol levels at the time of testing.²⁴ While that study focused on one country, delayed lipid screening for women is a recognized pattern in many healthcare systems, partly because cardiovascular disease has historically been framed as a male problem. The gap is not just a numbers curiosity; delayed detection means delayed intervention, which translates into preventable disease.

Even once you receive your results, what you do with them matters. Research on follow-up behavior found that patients who received an automatic plain-language interpretation of their abnormal lab results had a meaningfully higher follow-up rate, around 68% on average, compared with about 49% among patients who received only raw numbers without interpretation.²⁵ If your online patient portal shows flagged lipid values without much explanation, the research suggests that seeking out a clear interpretation, whether from your doctor, a pharmacist, or a credible resource, makes it significantly more likely you will actually act on the results.

Acute Illness and Misleading Lipid Values

If you had blood drawn while you were seriously ill, especially during an infection or a hospital stay, your lipid numbers may not represent your baseline. Acute illness can dramatically alter cholesterol and triglyceride levels. A study looking at pre-illness lipid profiles and sepsis outcomes found a U-shaped relationship: both very high and very low levels of LDL and triglycerides before sepsis were associated with increased mortality. The researchers concluded that some baseline lipid availability appears necessary for the body to mount an effective immune response, while extreme levels in either direction are harmful.²⁶ The practical takeaway: if your lipid panel was drawn during an acute illness or hospitalization, those numbers should not be used to make long-term decisions about statins or cardiovascular risk. Ask for a repeat test once you have recovered.